A Comparative Clinical Study of Unani Formulation (Maghz Tukhm-e-Jamun wa Tukhm-e-Hayat) and Metformin in the Management of Ziabetus Shakari (Type 2 Diabetes Mellitus)

Type 2 diabetes mellitus is a major health concern in the 21st century, which is largely preventable but remains responsible for millions of deaths annually and many life-threatening complications. The present study was conducted to evaluate and compare the efficacy of Withania coagulans Dunal and Eugenia jambolana Lam with that of standard control metformin in managing type 2 diabetes mellitus.
This was a randomized open study with standard control. A total of 60 diagnosed cases of type 2 diabetes mellitus were randomly allocated in the test (n = 30) and control groups (n = 30). Test drug, a combination of E. jambolana (6 g in powder form) and oral infusion of W. coagulans (10 pieces), and control drug metformin (500 mg) were administered to the participants twice daily for 90 days. The subjective parameters were assessed at every follow-up, blood sugar was recorded at a monthly interval, while hemoglobin A1c, RFT, and lipid profile were recorded at baseline and at the termination of the trial. The study outcome was analyzed using appropriate statistical tests. The test drug showed significant improvement at par to the control drug in subjective (polydipsia, polyphagia, fatigue, and weight loss) and objective (blood sugar, glycated hemoglobin, RFT, serum cholesterol, and serum triglyceride) parameters without any side effects or toxicity. The study inferred that the drug was safe and effective in managing type 2 diabetes mellitus.